Company news

Atara Biotherapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

October 14, 2026

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

September 30, 2026

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

August 12, 2026

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

May 12, 2026

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

April 1, 2026

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

March 16, 2026

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

March 3, 2026

Atara Biotherapeutics Provides a Business Update

February 23, 2026

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

January 12, 2026

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

November 12, 2025

Atara Biotherapeutics Announces Changes to Its Board of Directors

September 3, 2025

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

August 11, 2025

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

July 24, 2025

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

July 14, 2025

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

May 16, 2025

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

May 15, 2025

Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 15, 2025

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

May 5, 2025

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

March 7, 2025

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

January 20, 2025

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

January 15, 2025

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

November 11, 2024

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

November 4, 2024

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 3, 2024

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

September 3, 2024

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

September 2, 2024

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update

August 11, 2024

Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

August 6, 2024

Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

July 2, 2024

Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases

June 20, 2024

Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split

June 16, 2024

Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting

May 28, 2024

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

May 19, 2024

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

May 8, 2024

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

March 27, 2024

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

February 28, 2024

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

February 27, 2024

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

February 13, 2024

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

January 30, 2024

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

January 7, 2024

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

January 7, 2024

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

December 19, 2023

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

December 10, 2023

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 30, 2023

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

November 28, 2023

Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference

November 21, 2023

Atara Biotherapeutics To Participate at the Stifel Healthcare Conference

November 9, 2023

Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

November 7, 2023

Older news releases →

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.